# Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Canonical URL: https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-second-quarter-2025-financial-results-and-highlights-recent-activity
Ticker: IKT
Company: Inhibikase Therapeutics
Source: Inhibikase Therapeutics
Published: 2025-08-14 20:50 EST
Original Source URL: https://www.inhibikase.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-23 12:00 EST — [Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-fda-orphan-drug-designation-granted-to-ikt-001-b6d23765) — Source: Inhibikase Therapeutics
- 2026-07-14 12:00 EST — [Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-sale-of-50-million-of-shares-through-its-at-th-30edf4cb) — Source: Inhibikase Therapeutics
- 2026-07-02 20:01 EST — [Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-56-d71ac313) — Source: Inhibikase Therapeutics
- 2026-05-12 20:01 EST — [Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-first-quarter-2026-financial-results-and-highlights-recent-activity) — Source: Inhibikase Therapeutics
- 2026-04-07 12:00 EST — [Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension) — Source: Inhibikase Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)